FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Woman with PML Linked to MS Therapy Successfully Treated with IL-2 Cytokine




























A case report of a woman with relapsing-remitting MS, who developed progressive multifocal leukoencephalopathy (PML) after natalizumab therapy, found that the immune-boosting molecule interleukin-2 (IL-2) might be a viable therapeutic option to fight this life-threatening complication although further study is needed.

The case report, “Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature,“ was published in the journal Therapeutic Advances in Neurological Disorders.

PML, caused by the John Cunningham (JC) virus, is a rare but serious condition, the consequence of the treatment with natalizumab (Tysabri). Researchers and clinicians have tried various approaches to limit the infection, but none have proved successful so far.

The woman, 51, came to the attention of the clinical research team at UT Southwestern Medical Center when she developed expressive aphasia, the inability to speak, and became weak along the right side of her body. Magnetic resonance imaging (MRI) scans showed new brain lesions, and she tested positive for the JC virus. Her condition worsened despite plasmapheresis and immunoglobulin treatment, and she developed epileptic brain activity.

High levels of the virus were found in her cerebrospinal fluid, and the team started treating her with IL-2. The IL-2 cytokine triggers the development of cytotoxic T-cells that fight the virus, and has been used to treat PML in patients with blood cancers. Treatment with IL-2 may increase the risk of MS progression, but the research team deemed it to be a much lower risk than the potentially fatal consequences of PML.

When discontinuing natalizumab treatment, patients are at risk of developing what is known as immune reconstitution inflammatory syndrome (IRIS). This happens when the immune system starts to recover because an immunosuppressive or modulating therapy has been stopped, and reacts to a present infection so robustly it makes the symptoms worse. Since the boosting of T-cells by IL-2 might further increase the risk of IRIS, the woman also received high-dose corticosteroids to dampen inflammatory reactions.

Results showed that the woman gradually improved on the IL-2 therapy. Her speech returned and she regained muscle strength — features that were accompanied by lower virus levels and a disappearance of MRI lesions. She did not experience any severe side effects of the IL-2 treatment.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels: ,



Go to Newer News Go to Older News